Related Experiment Video
Updated: Dec 22, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
[Treatment of chronic heart failure: is deprescribing possible?]
O N Tkacheva1, O D Ostroumova1, Yu V Kotovskaya1
1Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University.
Abstract:
Deprescribing is a scheduled withdrawal, dose reduction, or replacement of a medicine with a safer one. Several groups of medicinal products (MPs) are used simultaneously in the treatment of chronic heart failure. This increases the risk of adverse drug reactions, particularly in elderly and senile patients. A systematic search for literature allowed evaluating possibilities of deprescribing for the following pharmaceutic groups: 1) MPs influencing the renin-angiotensin-aldosterone system; 2) beta-blockers; 3) digoxin; and 4) diuretics. Three systematic reviews and several studies were analyzed to determine the most feasible and potentially optimal regimens of deprescribing in CHF. It was established that in CHF, deprescribing has a very limited potential for use due to the documented, obvious effect of some MP groups on prediction and severity of clinical symptoms in CHF patients.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: β-Blockers
Heart Failure IV: Classification and Diagnostic Evaluation